• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 10th February 2015

Medical Research: How Long Does it Take?

It is surprisingly hard to measure how long medical research takes. A recently published study by OHE, Brunel and RAND Europe shows a better way to do that. In our blog post on 3rd February 2015 we described recent research…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
10-Feb-OHE-Lags-blog-Academic-chart

It is surprisingly hard to measure how long medical research takes. A recently published study by OHE, Brunel and RAND Europe shows a better way to do that.

In our blog post on 3rd February 2015 we described recent research aimed at analysing how long medical research takes from the first pound being spent to benefits being felt by patients or the general public as a result of that research.

Everyone would like to shorten that time span. But the information we have about just how long medical research does take to bear fruit is surprisingly hard to use to inform research policy and practice. Different studies measure elapsed times between different points in the research history of an innovation. They also measure elapsed times for a wide variety of very different kinds of innovations with rather different pathways between initial inspiration and eventual delivery of benefits: medicines, public health interventions, better ways to organise health services, and numerous other kinds of health care technology improvement.
 
We identified a need for a more consistent frame of reference for measuring time lags in medical research. Trochim and colleagues in 2011 described a “process marker model” which potentially contained a very large number of such process markers*. Data on most of those markers in the research history would either be unavailable for many technologies or infeasibly costly to track down. Furthermore, the complex and frequently non-linear nature of progression of research ideas through their translation (if successful) into routine use can be hard to represent that way.
 
As part of a recently completed research study funded by the UK Medical Research Council, OHE working with Brunel University London, RAND Europe and King’s College London, took a significant step forward in developing a method to measure time lags in biomedical and health research. See:
 
Hanney, S.R., Castle-Clarke, S., Grant, J., Guthrie, S., Henshall, C., Mestre-Ferrandiz, J., Pistollato, M., Pollitt, A., Sussex, J. and Wooding, S. 2015. How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy and practice. Health Research Policy and Systems, 13(1), pp.1-18. 
 
Having reviewed academic and policy literatures, we undertook detailed case studies of the research histories of seven very different health technologies: two medicines, a screening technology, a public health measure, behavioural therapies for two mental illnesses, and a service reorganisation aimed at early intervention.
 
Our approach to clearer measurement of elapsed times in research essentially comprises two main elements:
 
1. A matrix of the main tracks that medical research follows and how they interlink in the research history of a single health technology of any kind; and
2. A modest number of (unambiguous) calibration points between which elapsed times can be measured and compared across any kinds of medical technology.
 
The matrix is shown below. It consists of four main groups of tracks, two of which contain the research (discovery research and human research/research review) and two of which cover the clinical practice and public policy developments that mean the new technology gets used. The two middle groups each consist of a number of separate tracks. Some tracks (for example discovery research, research review and synthesis, policy development, and clinical practice) have an ongoing “life” of their own with activity in the track often pre-dating and continuing after the particular key events that cause work on a specific intervention to commence or cross from one track to another. This model allows analysis of elapsed times along a track and between the points at which a technology jumps from one track to another.
 

Source: Hanney et al., 2015.

Starting from a very long initial list obtained from the literature and our own research knowledge, we boiled that down to 11 key calibration points. These span a research history from the start date of the key research study to the inclusion of the technology in health service policy and/or formal guidance to health care providers such as clinical guidelines.
 
There remains much to do to analyse the length of time it takes for medical research to yield benefits, and hence to identify the areas where research could be accelerated without undue risks, and the policy changes needed to bring that acceleration about. But we have taken another step forward.
 
Access the full paper here
 
*Trochim, W., Kane, C., Graham, M. and Pincus, H.A. 2011. Evaluating translational research: a process marker model. Clinical and Translational Science, 4(3), pp.153-162.
  • Drug Development/R&D
  • Economics of Innovation
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!